92,427 Roivant Sciences Ltd. $ROIV Shares Acquired by Retirement Systems of Alabama

Retirement Systems of Alabama boosted its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 19.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 558,777 shares of the company’s stock after buying an additional 92,427 shares during the quarter. Retirement Systems of Alabama’s holdings in Roivant Sciences were worth $20,434,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP increased its holdings in Roivant Sciences by 179.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock worth $95,124,000 after acquiring an additional 1,724,588 shares during the last quarter. Maverick Capital Ltd. bought a new stake in Roivant Sciences in the 1st quarter valued at about $45,066,000. Assenagon Asset Management S.A. lifted its holdings in Roivant Sciences by 18.2% during the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock valued at $295,965,000 after purchasing an additional 1,286,464 shares during the last quarter. Affinity Asset Advisors LLC lifted its holdings in Roivant Sciences by 64.7% during the first quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company’s stock valued at $77,560,000 after purchasing an additional 1,100,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. bought a new position in Roivant Sciences during the third quarter worth about $35,624,000. Institutional investors own 64.76% of the company’s stock.

Insider Buying and Selling

In other Roivant Sciences news, insider Mayukh Sukhatme sold 144,756 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $36.48, for a total value of $5,280,698.88. Following the completion of the transaction, the insider owned 18,630,739 shares in the company, valued at $679,649,358.72. This trade represents a 0.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Melissa Epperly sold 17,750 shares of Roivant Sciences stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $36.10, for a total value of $640,775.00. Following the transaction, the director directly owned 14,954 shares of the company’s stock, valued at $539,839.40. The trade was a 54.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 2,022,688 shares of company stock valued at $73,438,636. Corporate insiders own 8.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ROIV. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Citigroup upped their price target on shares of Roivant Sciences from $46.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. Wolfe Research downgraded shares of Roivant Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, October 12th. Finally, Guggenheim lifted their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $46.64.

Roivant Sciences Trading Up 1.6%

Shares of NASDAQ ROIV opened at $41.85 on Thursday. Roivant Sciences Ltd. has a fifty-two week low of $19.96 and a fifty-two week high of $42.50. The stock has a fifty day moving average of $37.09 and a 200-day moving average of $32.08.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.